Rising adoption of minimally invasive treatments for chronic disorders across the globe will propel the growth of injectable nanomedicines market during the forecast period

The global injectable nanomedicines market touched USD 479.6 million in 2017, and is expected to reach USD 833.9 million by 2025, growing at a CAGR of 7.3% during 2018–2025.

Source: GMI Research

Major Factors driving the market growth are:
· Growing incidence of chronic diseases like cancer, cardiovascular diseases, neurological disorders
· Increasing research & development activities and clinical trials
· Rising demand and adoption of minimally invasive treatments
· Rising government and private funding
· Increasing geriatric population

Growing demand for minimal invasive treatments is driving the Injectable Nanomedicines market. Introduction of innovative and advanced nanotechnology and nanomedicines, especially in the emerging markets with the help of government and private funding would spur the growth of market for the injectable nanomedicines during the forecast period.

A paradigm shifts from traditional therapeutics to novel therapeutics using nanomedicines is propelling the overall market as nanomedicines have higher payload capacity, prolonged blood circulation times, reduced toxicity and improved anti-tumour efficacy. Moreover, the application of injectable nanomedicines for some widespread chronic diseases like migraine and depression is also aiding market growth. The use of injectable nanomedicines are found to be efficient, lasting and easy treatment of many chronic cardiovascular and neurological disorders.

Growing incidence rate due to aging demographic patterns and the extension of health insurance coverage in a developing region will support the market growth. Advancements in cancer drug delivery and personalized cancer treatments, effective and safe treatment of medically refractory movement disorders and the need for fast and efficient cardiovascular systems will primarily drive the global injectable nanomedicine market.

“The rising pool of patients of chronic diseases and the need for a fast, efficient and long-lasting treatment with minimal invasion procedures will drive the injectable nanomedicines market.”
—-GMI Research

Based on geography, North America held the largest market share in 2017 due to the significantly high rate of incidence of cancer as well as cardiovascular diseases in the region. Currently, the region has a growing demand for rapid research & development of novel nanomedicine in order to address unmet medical needs. Furthermore, favourable reimbursement policies and increasingly growing partnerships between leading enterprises and nanomedicine start-ups is also expected to create growth opportunities. Europe is the second largest market in 2017 and is promising market due to developed healthcare system and rising adoption of nanomedicine in oncology sector. Asia-Pacific is expected to show promising growth in global injectable nanomedicines during 2018-2025 due to the increasing government and private funding for health care infrastructure along with the rising incidence of neurological disorders. Moreover, increasing adoption of nanomedicine for the treatment of cancer, diabetes, cardiovascular diseases and some infectious disease in the Asia-Pacific region would also contribute significantly to the market growth for injectable nanomedicines in the region.

Based on geography, North America held the largest market share in 2017 due to the significantly high rate of incidence of cancer as well as cardiovascular diseases in the region. Currently, the region has a growing demand for rapid research & development of novel nanomedicine in order to address unmet medical needs. Furthermore, favourable reimbursement policies and increasingly growing partnerships between leading enterprises and nanomedicine start-ups is also expected to create growth opportunities. Europe is the second largest market in 2017 and is promising market due to developed healthcare system and rising adoption of nanomedicine in oncology sector. Asia-Pacific is expected to show promising growth in global injectable nanomedicines during 2018-2025 due to the increasing government and private funding for health care infrastructure along with the rising incidence of neurological disorders. Moreover, increasing adoption of nanomedicine for the treatment of cancer, diabetes, cardiovascular diseases and some infectious disease in the Asia-Pacific region would also contribute significantly to the market growth for injectable nanomedicines in the region.

Key takeaways/key essentials:
· In 2017, the cancer treatment held the major share for the injectable nanomedicines market followed by the cardiovascular diseases segment.
· High demand and adoption rate for minimally invasive treatments in the recent past.
· Extended research and development activities are taking place using the injectable nanomedicines regarding the concept of targeted drug delivery system.

Some of the key players operating in the global market for injectable nanomedicines include Merck & Co., Inc., Lupin, Pacira Pharmaceuticals Inc., Celgene Pharmaceutical Co. Ltd., Amgen, Inc., Janssen Biotech Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Inc. among others.

The global injectable nanomedicines market has been segmented based on product type, indication type and key geographies. Based on the product type, global injectable nanomedicines market has been segmented into liposomes, micelles, nanocrystals and others. Based on indication type, the market has been segmented into cancers, central nervous system diseases, cardiovascular diseases, inflammatory diseases and others.

The research report “global injectable nanomedicines market” provides in-depth analysis of injectable nanomedicines market, globally, based on product type, indication and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers fuelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for injectable nanomedicines market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For more details, browse the Table of Contents: https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/
Early buyers will get customization upto 20% on report

Contact Sarah Nash
Tel: +353 1 536 3035
U.S Office +1 860 881 2270
Europe Office +353 1 442 8820
Email: enquiry@gmiresearch.com